162 related articles for article (PubMed ID: 9855167)
1. Elevated tear interleukin-6 levels in patients with Sjögren syndrome.
Tishler M; Yaron I; Geyer O; Shirazi I; Naftaliev E; Yaron M
Ophthalmology; 1998 Dec; 105(12):2327-9. PubMed ID: 9855167
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome.
Yoon KC; Jeong IY; Park YG; Yang SY
Cornea; 2007 May; 26(4):431-7. PubMed ID: 17457192
[TBL] [Abstract][Full Text] [Related]
3. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease.
Solomon A; Dursun D; Liu Z; Xie Y; Macri A; Pflugfelder SC
Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2283-92. PubMed ID: 11527941
[TBL] [Abstract][Full Text] [Related]
4. Tear lipocalin and lysozyme in Sjögren and non-Sjögren dry eye.
Caffery B; Joyce E; Boone A; Slomovic A; Simpson T; Jones L; Senchyna M
Optom Vis Sci; 2008 Aug; 85(8):661-7. PubMed ID: 18677232
[TBL] [Abstract][Full Text] [Related]
5. Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non-Sjögren syndrome dry eye patients.
Lee SY; Han SJ; Nam SM; Yoon SC; Ahn JM; Kim TI; Kim EK; Seo KY
Am J Ophthalmol; 2013 Aug; 156(2):247-253.e1. PubMed ID: 23752063
[TBL] [Abstract][Full Text] [Related]
6. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome.
Argüeso P; Balaram M; Spurr-Michaud S; Keutmann HT; Dana MR; Gipson IK
Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1004-11. PubMed ID: 11923240
[TBL] [Abstract][Full Text] [Related]
7. [The evaluation of chosen cytokines in induction of ocular changes in Sjögren's syndrome of dry eye].
Zywalewska-Górna N; Mrugacz M; Bakunowicz-Lazarczyk A
Klin Oczna; 2007; 109(10-12):435-7. PubMed ID: 18488390
[TBL] [Abstract][Full Text] [Related]
8. Tear evaporation rates in Sjögren syndrome and non-Sjögren dry eye patients.
Goto E; Matsumoto Y; Kamoi M; Endo K; Ishida R; Dogru M; Kaido M; Kojima T; Tsubota K
Am J Ophthalmol; 2007 Jul; 144(1):81-85. PubMed ID: 17509507
[TBL] [Abstract][Full Text] [Related]
9. Meibomian gland dysfunction in patients with Sjögren syndrome.
Shimazaki J; Goto E; Ono M; Shimmura S; Tsubota K
Ophthalmology; 1998 Aug; 105(8):1485-8. PubMed ID: 9709762
[TBL] [Abstract][Full Text] [Related]
10. Salivary and serum interleukin 6 in primary Sjögren's syndrome.
Grisius MM; Bermudez DK; Fox PC
J Rheumatol; 1997 Jun; 24(6):1089-91. PubMed ID: 9195514
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of autoantibodies against a-fodrin in serum, tear fluid, and saliva from patients with Sjögren's syndrome.
Yavuz S; Toker E; Bicakcigil M; Mumcu G; Cakir S
J Rheumatol; 2006 Jul; 33(7):1289-92. PubMed ID: 16821267
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory markers in the tears of patients with ocular surface disease.
Acera A; Rocha G; Vecino E; Lema I; Durán JA
Ophthalmic Res; 2008 Oct; 40(6):315-21. PubMed ID: 18688174
[TBL] [Abstract][Full Text] [Related]
13. IL-10 promoter -1082 polymorphism is associated with elevated IL-10 levels in control subjects but does not explain elevated plasma IL-10 observed in Sjögren's syndrome in a Hungarian cohort.
Márka M; Bessenyei B; Zeher M; Semsei I
Scand J Immunol; 2005 Nov; 62(5):474-80. PubMed ID: 16305644
[TBL] [Abstract][Full Text] [Related]
14. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development.
Manoussakis MN; Boiu S; Korkolopoulou P; Kapsogeorgou EK; Kavantzas N; Ziakas P; Patsouris E; Moutsopoulos HM
Arthritis Rheum; 2007 Dec; 56(12):3977-88. PubMed ID: 18050195
[TBL] [Abstract][Full Text] [Related]
15. The significance of salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with Sjögren's syndrome.
Boras VV; Cikes N; Lukac J; Cekić-Arambasin A; Virag M; Bosnjak A
Coll Antropol; 2004; 28 Suppl 2():305-9. PubMed ID: 15571105
[TBL] [Abstract][Full Text] [Related]
16. Serum level of IL-6 in patients with primary and secondary Sjögren's syndrome.
Slezák R; Krejsek J; Kopecký O; Jelenová H
Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1995; 38(2):59-60. PubMed ID: 8584859
[TBL] [Abstract][Full Text] [Related]
17. Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjögren's syndrome patients.
Aragona P; Bucolo C; Spinella R; Giuffrida S; Ferreri G
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4474-9. PubMed ID: 16303936
[TBL] [Abstract][Full Text] [Related]
18. Elevated tear interleukin-6 and interleukin-8 levels in patients with conjunctivochalasis.
Erdogan-Poyraz C; Mocan MC; Bozkurt B; Gariboglu S; Irkec M; Orhan M
Cornea; 2009 Feb; 28(2):189-93. PubMed ID: 19158563
[TBL] [Abstract][Full Text] [Related]
19. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients.
Lee HK; Ryu IH; Seo KY; Hong S; Kim HC; Kim EK
Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of soluble CD44 in primary Sjögren's syndrome.
Levesque MC; Mackin DA; Fleming JA; St Clair EW
J Rheumatol; 2000 Jun; 27(6):1444-9. PubMed ID: 10852268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
